Table 1 Distribution of vaccine doses during the evaluated period by geographic region for priority groups. Brazil, 2021
From: The assistance gaps in combating COVID-19 in Brazil: for whom, where and when vaccination occurs
Region | Group | CoronaVac | AstraZeneca | |||||||
|---|---|---|---|---|---|---|---|---|---|---|
1st dose n (%) | 2nd dose n (%) | Fully vaccinated | VR | 1st dose n (%) | 2nd dose n (%) | Fully vaccinated | VR | Total | ||
EP | 750,200 (5.1) | 650,326 (5.1) | 86.69% | 39.56 | 608,189 (6.0) | 153,563 (13.9) | 25.25% | 9.34 | 2,162,258 (5.6) | |
60—64 | 210,856 | 173,437 | 82.25% | 30.96 | 215,295 | 10,185 | 4.73% | 1.82 | 609,773 | |
65—69 | 195,078 | 166,828 | 85.52% | 40.23 | 150,793 | 29,303 | 19.43% | 7.06 | 542,002 | |
N | 70—74 | 141,272 | 123,985 | 87.76% | 43.89 | 101,189 | 41,880 | 41.39% | 14.83 | 408,326 |
75—79 | 95,142 | 86,415 | 90.83% | 46.01 | 65,160 | 30,020 | 46.07% | 15.98 | 276,737 | |
80 + | 107,852 | 99,661 | 92.40% | 50.11 | 75,732 | 42,175 | 55.69% | 21.2 | 325,420 | |
HW | 264,925 (6.4) | 234,436 (6.3) | 88.49% | 58.61 | 133,992 (4.4) | 61,198 (5.7) | 45.67% | 15.3 | 694,551 (5.8) | |
I/Q | 135,357 (39.3) | 90,021 (33.4) | 66.51% | 26.27 | 168,625 (29.9) | 2,280 (12.6) | 0.38% | 0.18 | 394,638 (33.6) | |
EP | 3,734,105 (25.4) | 3,187,557 (25.1) | 85.36% | 43.97 | 2,343,992 (23.3) | 240,741 (21.8) | 10.31% | 3.32 | 9,506,395 (24.6) | |
60—64 | 491,638 | 372,465 | 75.76% | 17.09 | 1,095,861 | 6,657 | 0.61% | 0.3 | 1,996,621 | |
65—69 | 1,084,657 | 904,680 | 83.40% | 52.75 | 504,901 | 3,778 | 0.75% | 0.22 | 2,498,016 | |
NE | 70—74 | 1,001,896 | 869,803 | 86.82% | 65.32 | 125,146 | 3,317 | 2.65% | 0.25 | 2,000,162 |
75—79 | 640,426 | 571,529 | 89.24% | 62.53 | 158,042 | 32,892 | 20.81% | 3.6 | 1,402,889 | |
80 + | 515,488 | 469,080 | 91.00% | 42.24 | 460,042 | 194,097 | 42.19% | 17.48 | 1,638,707 | |
HW | 1,123,282 (27.2) | 980,223 (26.4) | 87.26% | 59.01 | 680,190 (22.3) | 210,086 (19.6) | 30.88% | 11.69 | 2,993,781 (25.0) | |
I/Q | 100,211 (29.1) | 84,415 (31.3) | 84.23% | 36.87 | 291,254 (51.7) | 1,217 (6.7) | 0.42% | 0.53 | 477,097 (40.6) | |
EP | 6,827,568 (46.4) | 5,813,281 (45.7) | 85.14% | 40.65 | 4,673,492 (46.4) | 476,824 (43.3) | 10.20% | 3.33 | 17,791,165 (46.1) | |
60—64 | 418,011 | 288,525 | 69.02% | 6.51 | 2,563,521 | 16,045 | 0.62% | 0.36 | 3,286,102 | |
65—69 | 2,293,383 | 1,831,421 | 79.86% | 52.52 | 1,087,506 | 14,332 | 1.32% | 0.41 | 5,226,642 | |
SE | 70—74 | 2,006,187 | 1,760,628 | 87.76% | 69.29 | 86,999 | 11,163 | 12.83% | 0.44 | 3,864,977 |
75—79 | 1,103,770 | 1,009,949 | 91.50% | 59.96 | 315,599 | 120,220 | 38.09% | 7.14 | 2,549,338 | |
80 + | 1,006,217 | 922,758 | 91.70% | 42.77 | 619,867 | 315,064 | 50.83% | 14.6 | 2,863,906 | |
HW | 1,809,235 (43.8) | 1,638,179 (44.1) | 90.54% | 49.64 | 1,504,349 (49.4) | 473,990 (44.2) | 68.49% | 14.36 | 5,425,753 (45.3) | |
I/Q | 21,766 (6.3) | 19,498 (7.2) | 89.58% | 19.92 | 67,072 (11.9) | 1,039 (5.7) | 1.55% | 1.06 | 109,375 (9.3) | |
EP | 1,029,113 (7.0) | 943,128 (7.4) | 91.64% | 47.6 | 717,314 (7.1) | 95,018 (8.6) | 13.25% | 4.8 | 2,784,573 (7.2) | |
60—64 | 107,534 | 84,939 | 79.00% | 12.87 | 423,699 | 5,874 | 1.39% | 0.89 | 631,046 | |
65—69 | 318,153 | 286,917 | 90.18% | 57.86 | 123,310 | 3,814 | 3.09% | 0.77 | 732,194 | |
CW | 70—74 | 296,639 | 280,162 | 94.45% | 80.6 | 27,095 | 3,796 | 14.01% | 1.09 | 607,692 |
75—79 | 152,013 | 144,937 | 95.35% | 63.69 | 60,422 | 29,984 | 49.62% | 12.87 | 387,356 | |
80 + | 154,774 | 146,173 | 94.44% | 58.39 | 82,788 | 51,550 | 62.27% | 20.59 | 435,285 | |
HW | 314,342 (7.6) | 296,655 (8.0) | 86.91% | 45.63 | 335,254 (11.0) | 128,553 (12.0) | 39.35% | 19.78 | 1,074,804 (9.0) | |
I/Q | 58,054 (16.9) | 50,220 (18.6) | 86.06% | 35.08 | 20,419 (3.6) | 13,468 (74.4) | 18.86% | 1.79 | 124,448 (10.6) | |
EP | 2,365,842 (16.1) | 2,115,986 (16.6) | 89.44% | 42.15 | 1,718,530 (17.1) | 136,100 (12.3) | 7.92% | 2.71 | 6,336,458 (16.4) | |
60—64 | 143,740 | 69,700 | 48.49% | 4.49 | 1,051,051 | 3,047 | 0.29% | 0.2 | 1,267,538 | |
65—69 | 900,508 | 747,100 | 82.97% | 60.41 | 351,166 | 1,765 | 0.50% | 0.14 | 2,000,539 | |
S | 70—74 | 711,984 | 642,083 | 90.18% | 70.85 | 30,871 | 923 | 2.99% | 0.1 | 1,385,861 |
75—79 | 407,658 | 372,413 | 91.36% | 62 | 71,336 | 16,067 | 22.52% | 2.67 | 867,474 | |
80 + | 201,952 | 284,690 | 140,97%a | 39.31 | 214,106 | 114,298 | 53.38% | 15.78 | 815,046 | |
HW | 619,281 (15.0) | 566,713 (15.2) | 91.51% | 51.52 | 391,701 (12.9) | 199,019 (18.6) | 50.81% | 18.09 | 1,776,714 (14.8) | |
I/Q | 28,877 (8.4) | 25,392 (9.4) | 87.93% | 32.62 | 16,283 (2.9) | 108 (1.9%) | 0.66% | 0.14 | 70,660 (6.0) | |
Total EP | 14,706,828 (76.7) | 12,710,278 (76.1) | 86.42% | 42.09 | 10,061,497 (73.6) | 1,102,246 (50.5) | 10.96% | 3.65 | 38,580,849 (74.6) | |
Total 60–64 | 1,371,779 | 989,066 | 71.88% | 10.54 | 5,349,427 | 41,808 | 0.78% | 0.44 | 7,749,080 | |
Total 65–69 | 4,791,779 | 3,936,946 | 82.16% | 53.57 | 2,217,676 | 52,992 | 2.39% | 0.72 | 10,999,393 | |
Total 70–74 | 4,157,978 | 3,676,661 | 88.42% | 67.98 | 371,300 | 61,079 | 16.45% | 1.13 | 8,267,018 | |
Total 75–79 | 2,399,009 | 2,185,243 | 91.09% | 60.46 | 670,559 | 229,183 | 34.18% | 6.34 | 5,483,994 | |
Total 80 + | 1,986,283 | 1,922,362 | 96.78% | 43.29 | 1,452,535 | 717,184 | 49.37% | 16.15 | 6,078,364 | |
Total HW | 4,131,065 (21.5) | 3,716,206 (22.3) | 89.96% | 50.9 | 3,045,486 (22.3) | 1,072,846 (49.2) | 64.77% | 14.69 | 11,965,603 (23.1) | |
Total I/Q | 344,265 (1.8) | 269,546 (1.6) | 78.30% | 30.27 | 556,841 (4.1) | 5,521 (0.3) | 0.99% | 0.62 | 1,176,173 (2.3) | |
Total per dose | 19,182,158 (100.0) | 16,696,030 (100.0) | 87.04% | – | 13,663,824 (100.0) | 2,180,613 (100.0) | 15.96% | – | 51,722,625 (100.0) | |
Total | 35,878,188 (100.0) | 15,844,437 (100.0) | 51,722,625 (100.0) | |||||||